Results 41 to 50 of about 6,042 (221)

Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis

Dermatology and Therapy, 2023
Introduction The aim of this study was to evaluate guselkumab efficacy on regional psoriasis in a subset of psoriasis patients with a self-reported psoriatic arthritis (PsA) diagnosis.
Ana-Maria Orbai, Soumya D. Chakravarty, Yin You, May Shawi, Ya-Wen Yang, Joseph F. Merola   +5 more
doaj   +1 more source

Development and validation of immunoassays for monitoring of guselkumab and anti-guselkumab antibodies in patients with moderate-to-severe psoriasis [PDF]

, 2020
Therapeutic drug monitoring, which is the measurement of drug concentrations in the blood, is a useful tool to guide clinical decision-making and treatment adjustments, on the condition that drug concentrations are correlated with treatment response. For
Brouwers, Els, Compernolle, Griet, Gils, Ann, Grine, Lynda, Imbrechts, Maya, Peeters, Miet, Soenen, Rani, Truffot, Aurélie, Van den Berghe, Nathalie   +8 more
core   +1 more source

Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study – IL PSO (ITALIAN LANDSCAPE PSORIASIS) [PDF]

, 2023
BackgroundGuselkumab is a humanized monoclonal antibody that binds selectively to the p19 subunit of interleukin-23, which has shown efficacy in patients with previous incomplete response to ustekinumab in the NAVIGATE clinical trial.
Angileri R. G., Bardazzi F., Bernardini N., Burlando M., Carrera C. G., Chiricozzi A., Costanzo A., Dapavo P., Dini V., Fabbrocini G., Gaiani F. M., Galluzzo M., Gargiulo L., Giofré C., Guarneri C., Ibba L., Loconsole F., Malagoli P., Malara G., Marcelli L., Megna M., Narcisi A., Piaserico S., Talamonti M.   +23 more
core   +1 more source

Guselkumab [PDF]

Reactions Weekly, 2020
Deep Joshipura, Brooke Rothstein, David Rosmarin   +2 more
  +4 more sources

Guselkumab binding to CD64+ IL-23–producing myeloid cells enhances potency for neutralizing IL-23 signaling

Frontiers in Immunology
IL-23 is implicated in the pathogenesis of immune-mediated inflammatory diseases, and myeloid cells that express Fc gamma receptor 1 (FcγRI or CD64) on their surface have been recently identified as a primary source of IL-23 in inflamed tissue.
Kacey L. Sachen, Deepa Hammaker, Indra Sarabia, Brian Stoveken, John Hartman, Kristin L. Leppard, Nicholas A. Manieri, Phuc Bao, Carrie Greving, Eilyn R. Lacy, Matthew DuPrie, Joshua Wertheimer, Janise D. Deming, Joseph Brown, Amy Hart, He (Hurley) Li, Tom C. Freeman, Brice Keyes, Kristen Kohler, Ian White, Nathan Karpowich, Ruth Steele, M. Merle Elloso, Steven Fakharzadeh, Kavitha Goyal, Frédéric Lavie, Maria T. Abreu, Matthieu Allez, Raja Atreya, Robert Bissonnette, Kilian Eyerich, Kilian Eyerich, James G. Krueger, Dennis McGonagle, Iain B. McInnes, Christopher Ritchlin, Anne M. Fourie   +36 more
doaj   +1 more source

Matching-adjusted indirect comparison (MAIC) results confirmed by head-to-head trials: a case study in psoriasis

Journal of Dermatological Treatment, 2023
Background Head-to-head comparisons through randomized controlled trials (RCTs) provide high-quality evidence to inform healthcare decisions. In their absence, indirect comparisons are often performed; however, evidence is limited on how valid matching ...
James Signorovitch, Joris Diels, Suzy Van Sanden, Agata Schubert, Fareen Hassan, Pushpike Thilakarathne, Bulent Ozturk, Norma Barthelmes, Kristian Reich   +8 more
doaj   +1 more source

Pharmacologic modulation of RORγt translates to efficacy in preclinical and translational models of psoriasis and inflammatory arthritis. [PDF]

, 2016
The IL-23/IL-17 pathway is implicated in autoimmune diseases, particularly psoriasis, where biologics targeting IL-23 and IL-17 have shown significant clinical efficacy.
Albers, Michael, Banie, Homayon, Budelsky, Alison L., Castro, Glenda, De Leon-Tabaldo, Aimee, Fourie, Anne M., Fung-Leung, Wai-Ping, Leonard, Kristi, Luna-Roman, Rosa, Rozenkrants, Natasha, Sablad, Marciano, Santamaria Babí, Luis F., Schlueter, Thomas, Soroosh, Pejman, Xue, Xiaohua, Yu, Jingxue   +15 more
core   +1 more source

Comparing Efficacy of Guselkumab versus Ustekinumab in Patients with Psoriatic Arthritis: An Adjusted Comparison Using Individual Patient Data from the DISCOVER and PSUMMIT Trials

Rheumatology and Therapy
Introduction Two biologic therapies for psoriatic arthritis (PsA), guselkumab and ustekinumab, have demonstrated superior efficacy versus placebo in clinical trials.
Pushpike Thilakarathne, Agata Schubert, Steve Peterson, Wim Noel, Barkha P. Patel, Fareen Hassan   +5 more
doaj   +1 more source

Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy

JID Innovations
Background: Psoriasis is an immune-mediated inflammatory disease characterized by activation of IL-23–driven IL-17–producing T cell and other IL-23 receptor–positive IL-17–producing cell responses.
Andrew Blauvelt, Richard G. Langley, Patrick J. Branigan, Xuejun Liu, Yanqing Chen, Samuel DePrimo, Keying Ma, Brittney Scott, Kim Campbell, Ernesto J. Muñoz-Elías, Kim A. Papp   +10 more
doaj   +1 more source

Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo‐Controlled DISCOVER‐1 Study

ACR Open Rheumatology, 2023
Objective To evaluate efficacy and safety of the interleukin‐23p19‐subunit inhibitor, guselkumab, in DISCOVER‐1 patients with active psoriatic arthritis (PsA) by prior use of tumor necrosis factor inhibitor (TNFi).
Christopher T. Ritchlin, Atul Deodhar, Wolf‐Henning Boehncke, Enrique R. Soriano, Alexa P. Kollmeier, Xie L. Xu, Federico Zazzetti, May Shawi, Yusang Jiang, Shihong Sheng, Philip S. Helliwell   +10 more
doaj   +1 more source